Title
The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.

Permalink
https://escholarship.org/uc/item/34f46044

Journal
The Journal of Clinical Endocrinology and Metabolism, 103(2)

ISSN
0021-972X

Authors
Mohler, Emile R
Ellenberg, Susan S
Lewis, Cora E
et al.

Publication Date
2018-02-01

DOI
10.1210/jc.2017-02243

Peer reviewed
THE EFFECT OF TESTOSTERONE ON CARDIOVASCULAR BIOMARKERS IN THE TESTOSTERONE TRIALS

Emile R Mohler III, MD, Susan S. Ellenberg, PhD, Cora E Lewis, MD, MSPH, Nanette K Wenger, MD, MACC, MACP, FAHA, Matthew J Budoff, MD, Michael R. Lewis, MD, Elizabeth Barrett-Connor, MD, Ronald S Swerdlow, MD, Alisa Stephens-Shields, PhD, Shalender Bhasin, MD, Jane A Cauley, DrPH, Jill P Crandall, MD, Glenn R Cunningham, MD, Kristine E Ensrud, MD, MPH, Thomas M Gill, MD, Alvin M Matsumoto, MD, Mark E Molitch, MD, Marco Pahor, MD, Peter E. Preston, MS, Xiaoling Hou, MS, Denise Cifelli, MS, Peter J Snyder, MD

The Journal of Clinical Endocrinology & Metabolism
Endocrine Society

Submitted: October 10, 2017
Accepted: December 11, 2017
First Online: December 14, 2017

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising references to, products or publications do not imply endorsement of that product or publication.
Effect of Testosterone on Cardiovascular Biomarkers

THE EFFECT OF TESTOSTERONE ON CARDIOVASCULAR BIOMARKERS IN THE TESTOSTERONE TRIALS

Emile R Mohler III, MD1*, Susan S. Ellenberg, PhD2, Cora E Lewis, MD, MSPH3, Nanette K Wenger, MD, MACC, MACP, FAHA4, Matthew J Budoff, MD5, Michael R. Lewis, MD6, Elizabeth Barrett-Connor, MD7, Ronald S Swerdloff, MD8, Alisa Stephens-Shields, PhD9, Shalender Bhasin, MD9, Jane A Cauley, DrPH10, Jill P Crandall, MD11, Glenn R Cunningham, MD12, Kristine E Ensrud, MD, MPH13,14, Thomas M Gill, MD15, Alvin M Matsumoto, MD16, Mark E Molitch, MD17, Marco Pahor, MD18, Peter E. Preston, MS2, Xiaoling Hou, MS2, Denise Cifelli, MS2, Peter J Snyder, MD19

*Deceased

1 Section of Vascular Medicine, Division of Cardiovascular Disease, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA
2 Division of Biostatistics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA
3 Division of Preventive Medicine, University of Alabama at Birmingham, AL, USA
4 Department of Medicine, Division of Cardiology, Emory Heart and Vascular Center Emory University School of Medicine, Atlanta, GA, USA
5 Los Angeles Biomedical Research Institute, Division of Cardiology, Harbor-University of California at Los Angeles Medical Center, Torrance, CA, USA
6 Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, VT, USA
7 Department of Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego School of Medicine, La Jolla, CA, USA
8 Los Angeles Biomedical Research Institute, Division of Endocrinology, Harbor-University of California at Los Angeles Medical Center, Torrance, CA, USA
9 Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
10 Department of Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 1 USA
11 Divisions of Endocrinology and Geriatrics, Albert Einstein College of Medicine, Bronx, NY, USA
12 Departments of Medicine and Molecular & Cellular Biology, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine and Baylor St. Luke's Medical Center, Houston, TX, USA
13 Department of Medicine, Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, MN, USA
14 Minneapolis VA Health Care System, Minneapolis, MN, USA
15 Section of Geriatric Medicine, Yale School of Medicine, New Haven, CT, USA
16 Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs, Puget Sound Health System, and Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle WA
17 Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
18 Department of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA
Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Received 10 October 2017. Accepted 11 December 2017.

**Context:** Studies of the possible cardiovascular risk of testosterone treatment are inconclusive.

**Objective:** To determine the effect of testosterone treatment on cardiovascular (CV) biomarkers in older men with low testosterone.

**Design:** Double-blind, placebo-controlled trial

**Setting:** Twelve academic medical centers in the United States

**Participants:** 788 men ≥65 years old with an average of two serum testosterone levels <275 ng/dL who were enrolled in The Testosterone Trials.

**Intervention:** Testosterone gel, the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months.

**Main Outcome Measures:** Serum markers of cardiovascular risk, including lipids and markers of glucose metabolism, fibrinolysis, inflammation, and myocardial damage.

**Results:** Testosterone treatment, compared to placebo, significantly decreased total cholesterol (adjusted mean difference -6.1 mg/dL, p<0.001), high density lipoprotein (HDL) cholesterol (adjusted mean difference -2.0 mg/dL, p<0.001) cholesterol and low density lipoprotein (LDL) cholesterol (adjusted mean difference -2.3 mg/dL, p=0.051) from baseline to month 12. Testosterone also slightly but significantly decreased fasting insulin (adjusted mean difference -1.7 µIU/mL, p=0.02) and HOMA-IR (adjusted mean difference -0.6, p=0.03). Testosterone did not change triglycerides, D-dimer, C-reactive protein, interleukin-6, troponin, glucose or HgbA1c more than placebo.

**Conclusions and Relevance:** Testosterone treatment for one year of older men with low testosterone was associated with small reductions in cholesterol and insulin but not with other glucose markers or markers of inflammation or fibrinolysis or with troponin. The clinical importance of these findings is unclear and requires a larger trial of clinical outcomes.

**INTRODUCTION**

The effect of testosterone treatment on cardiovascular risk is uncertain. Some retrospective studies using electronic medical records have reported more cardiovascular adverse events in men taking testosterone than in men not taking it, but others have not. These studies all have the limitations of not being controlled for diagnosis or treatment. One clinical trial of testosterone in frail older men was stopped early because more cardiovascular adverse events occurred in men taking testosterone than in men taking placebo, but another similar trial reported few adverse cardiovascular events. Meta-analyses of clinical trials have generally not shown more adverse cardiovascular events in men taking testosterone than in men taking placebo, but none of the individual trials was designed prospectively to capture these events.

The Testosterone Trials (TTrials) were a group of seven coordinated trial in 788 men to determine the efficacy of raising the serum testosterone levels of men ≥65 years to normal for young men for one year. Although the numbers of men who experienced major adverse cardiovascular events were similar in the two treatment arms in all men in the TTrials, testosterone treatment was associated with a greater increase in noncalcified coronary artery plaque volume by computed tomographic angiography in the 138 men who participated in the Cardiovascular Trial.
If testosterone does affect cardiovascular risk, it might do so by altering any one of several cardiovascular risk factors, such as lipids, glucose metabolism, coagulation and inflammation. We therefore measured several biomarkers of cardiovascular risk at baseline and after 3 and 12 months of treatment in all men participating in the TTrials.

METHODS

Study Design
The TTrials were a coordinated group of seven double-blind, placebo-controlled trials designed to evaluate the efficacy of testosterone treatment in men ≥65 years who had age-related low testosterone levels. To participate in the TTrials, a man had to qualify for at least one of the three main trials (Sexual Function, Physical Function and Vitality). Those who qualified could also participate in any of the other trials if they met the respective entry criteria. The participants were allocated to receive testosterone or placebo gel for one year. This report describes the serum levels of cardiovascular biomarkers at baseline and months 3 and 12 in all men participating in the TTrials.

The institutional review boards of the 12 participating sites approved the TTrials protocols. Before trial-related procedures were conducted, all participants provided written informed consent. An independent Data and Safety Monitoring Board oversaw participant safety and trial conduct.

Participants
The inclusion and exclusion criteria have been published. In brief, men were included who were ≥65 years, had serum testosterone levels that averaged <275 ng/dL on two morning samples and had a subjective and objective evidence of sexual dysfunction, physical dysfunction and/or reduced vitality. Men were excluded who were at moderate or high risk for prostate cancer, had a myocardial infarction within the previous three months, or had a blood pressure >160 mm Hg systolic or 100 mm Hg diastolic, serum creatinine >2.2 mg/dL or hemoglobin A1c >8.5%. Men were who were taking medications to control blood pressure or serum lipids were not excluded.

Testosterone Treatment
Men were allocated to receive either testosterone as a 1% gel in a pump bottle (AndroGel, AbbVie) or similar placebo gel in a double-blind fashion for one year. The initial dose of testosterone was 5g a day. The dose was adjusted to keep the serum concentration within the normal range for young men on the basis of measurement in a central laboratory (Quest Clinical Trials, Valencia, CA) at months 1, 2, 3, 6 and 9. To maintain the blind, when the dose was changed in a man taking testosterone, the dose was also changed in a man taking placebo.

Assessments
Blood for cardiovascular biomarkers was drawn fasting in the morning at baseline and months 3 and 12; serum was stored at -80°C. Biomarker assays were performed at the Laboratory for Clinical Biochemistry Research, University of Vermont, with the exception of the troponin I assay, which was performed at the University of Minnesota. Samples from the same participant were assayed in the same batch. Clinical variables were measured at baseline and months 3, 6, 9 and 12.

Lipid Assays
Lipid assays included total cholesterol (interassay CV range 1.45-2.33%), high density lipoprotein (HDL) cholesterol (interassay CV range 1.69-2.26%), and triglycerides (interassay...
CV range 1.95-2.57%) using enzymatic colorimetric assays (Cobas Integra 400, Roche Diagnostics, Indianapolis, IN). Low density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula when the triglyceride concentration was <400 mg/dL.

**Glucose, Insulin and Hemoglobin A1c Assays**

Glucose concentration was determined using a hexokinase method (Cobas Integra 400, Roche Diagnostics, Indianapolis, IN) (interassay CV range 2.24-4.55%).

Insulin was measured by electrochemiluminescence immunoassay (Elecsys 2010, Roche Diagnostics, Indianapolis, IN) (interassay CV range 2.39-2.78%).

HbA1c was measured in frozen whole blood samples by turbidmetric inhibition immunoassay (Tina-quant HgA1C Gen 2 Whole Blood application, Cobas Integra 400, Roche Diagnostics, Indianapolis, IN) (interassay CV range 1.63-3.25%).

**Assays of Markers of Inflammation**

C-reactive protein (CRP) was measured using a high-sensitivity particle enhanced immunonephelometric assay (BNII nephelometer; Siemens, Inc., Deerfield, IL) (interassay CV range 3.32-4.64%). Interleukin-6 (IL-6) was measured by electrochemiluminescence immunoassay (Meso Scale Diagnostics, Rockville, MD) (interassay CV range 8.14-11.95%).

**D-Dimer and Troponin Assays**

D-dimer was measured using an immunoturbidimetric assay (STA-R Evolution, Diagnostica Stago, Parsippany, NJ) (interassay CV range 2.73-20.14%).

Troponin I was measured using a high-sensitivity immunoassay (ARCHITECT STAT high-sensitive troponin I assay; Abbott Laboratories, Abbott Park, IL).

**Statistical analyses**

The effects of testosterone were assessed using random effects models for longitudinal data. The models included visit time as a categorical variable and a single main effect for treatment, and adjusted for baseline values of each biomarker and all balancing variables used in the allocation procedure: study site, indicator variables of participation in each primary efficacy trial, baseline testosterone concentration (≤ or >200 ng/dL), age (≤ or > 75), use of anti-depressants, and use of PDE-5 inhibitors. All participants who had at least one post-baseline value were included in the intent-to-treat analysis. We performed additional analyses of lipid markers excluding men who were not taking lipid-lowering medications at baseline but initiated them during the study; we also performed separate analyses of metabolic markers excluding men taking antidiabetic medications. Significance was assessed through the two-sided Wald test and confidence interval for the treatment effect. The treatment effect denotes the average difference in response by treatment arm across all visits (baseline, months 3 and 12). No adjustments were made for multiple testing.

**RESULTS**

**Participants and Clinical Measures**

Trials enrollment was 788 men at 12 sites. The mean age at baseline was 72 years. Relatively high percentages were obese and had co-morbid conditions, such as diabetes and hypertension, but the two treatment arms were well balanced for these conditions and related medications (Table 1). Testosterone treatment increased the serum testosterone concentration from unequivocally low at baseline to mid-normal for young men by month 3 and maintained it at that level through month 12[^10]. Testosterone treatment, compared to placebo, did not significantly
change weight (adjusted difference 0.28 kg, p = 0.18), BMI (adjusted difference 0.09 kg/m², p = 0.21) or waist/hip ratio (adjusted difference 0.002, p = 0.46) (Table 2).

Lipids
Serum concentrations of lipids (Table 3) were evaluated for all men and then separately for men who were either consistently taking or not taking lipid-lowering drugs during the 12 months of treatment. Levels at baseline were slightly lower in men in the testosterone arm (total cholesterol 161.9 mg/dL; HDL cholesterol, 44.5 mg/dL; LDL cholesterol, 87.9 mg/dL) than in men in the placebo arm (total cholesterol 167.8 mg/dL; HDL, 45.5 mg/dL; LDL, 91.8 mg/dL). Lipid levels decreased during the 12 months of treatment in both treatment arms. Adjusting for baseline levels and balancing factors, the men treated with testosterone had a reduction in total cholesterol 6.1 mg/dL greater than men treated with placebo (p<0.001). Reductions in HDL cholesterol (adjusted difference -2.0 mg/dL, p<0.001) and in non-HDL cholesterol (adjusted difference -4.2, p=0.005) were also greater in men treated with testosterone than men treated with placebo. Change in LDL cholesterol was marginally greater in the testosterone arm; the adjusted difference in change was 2.3 mg/dL, p=0.051). Reductions in triglyceride values were not significantly associated with treatment assignment.

Eleven men in the testosterone arm and four in the placebo arm initiated lipid-lowering medication after baseline. To assess the impact of these medication changes, we performed an analysis excluding these 15 men; the results changed minimally.

Markers of Glucose Metabolism
We evaluated markers that reflect glucose metabolism (Table 4) in all men and separately in men who were not taking medications for diabetes during the trial. Mean levels were similar in the 2 treatment groups at baseline (fasting glucose, 114.4mg/dL vs 116.0 mg/dL; fasting insulin, 18.6 µU/mL vs 18.1 µU/mL; Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), 5.8 vs 5.9; HgbA1c, 6.3% vs 6.3%, in the testosterone and placebo arms, respectively). Changes from baseline in these markers were small in both groups, but some differences in the changes between treatment arms were statistically significant (glucose, 1.3 mg/dL vs 2.2 mg/dL, adjusted difference -1.5 mg/dL, p = 0.30; insulin, -1.8 µU/mL vs -0.7 µU/mL, adjusted difference -1.7 µU/mL, p=0.02; HOMA-IR, 0.3 vs -0.2, adjusted difference -0.6, p=0.03; HgbA1c, 0.0% vs 0.1%, adjusted difference -0.07%, p=0.09, for men in the testosterone group vs placebo group, respectively. Evaluation of these markers in men not taking antidiabetic medications showed no statistically significant effect of testosterone.

Other Markers
We also measured D-dimer as a marker of fibrolysis, C-reactive protein (CRP) and interleukin-6 (IL-6) as markers of inflammation, and troponin as a marker of myocardial damage (Table 5). All showed similar mean baseline values (D-dimer, 0.7 mg/L vs 0.7 mg/L; CRP, 3.5 mg/L vs 3.5 mg/L; IL-6, 1.9 pg/mL vs 2.0 pg/mL; troponin, 7.6 ng/L vs 9.1 ng/L, in the testosterone and placebo groups, respectively. Mean changes from baseline were small and similar between treatment groups (D-dimer, 0.1 mg/L vs 0.1 mg/L, adjusted difference 0.01, p=0.69; CRP, -0.7 mg/L vs -0.1 mg/L, adjusted difference -0.6 mg/L, p=0.11; IL-6, 0.9 pg/ml vs 0.2 pg/mL, adjusted difference 0.2 pg/mL, p=0.67; troponin, 2.4 ng/L vs 0.1 ng/mL, adjusted difference 0.9 mg/L, p=0.37.

Because testosterone treatment was associated with a greater increase in coronary artery plaque volume in the 138 men who participated in the Cardiovascular Trial, we repeated all of the analyses of the effect of testosterone in just the 138 men who participated in the
Cardiovascular Trial. The results were similar in these 138 men to the results in all TTrials participants.

DISCUSSION

In The Testosterone Trials, raising the serum testosterone concentrations of men ≥65 years who had low baseline testosterone to normal levels for young men for one year did not affect weight, BMI or waist/hip ratio but decreased slightly serum concentrations of total, HDL and LDL cholesterol. The total cholesterol/HDL cholesterol ratio was not altered. Testosterone treatment also decreased slightly markers of insulin resistance but did not change fasting glucose or hemoglobin A1c levels. Testosterone treatment did not change appreciably markers of inflammation, fibrinolysis or myocardial damage.

Prior trials of the effects of injectable testosterone esters on serum lipids in hypogonadal men have also demonstrated small reductions in serum total, HDL and LDL cholesterol.\textsuperscript{12} Meta-analyses of testosterone trials that included variable entry criteria for participants, routes of administration and doses have shown inconsistent effects on cholesterol.\textsuperscript{8,13} In a double-blind crossover study of injectable testosterone versus placebo in 24 hypogonadal men with type 2 diabetes, testosterone treatment was associated with improved insulin sensitivity and glycated hemoglobin levels,\textsuperscript{14} but meta-analyses have generally not reported an effect of testosterone on glucose metabolism.\textsuperscript{8} Several studies have shown no clear effects of testosterone treatment on various inflammatory markers.\textsuperscript{15-17}

Compared to the effect of statin drugs on lowering LDL cholesterol, the effect of testosterone in this trial is quite small. Statin drugs, in doses used clinically, lower LDL cholesterol by 10-80 mg/dL,\textsuperscript{18} compared to the mean reduction of 2.3 mg/dL associated with testosterone treatment in this trial. Compared to the effect of statin drugs raising HDL cholesterol, the effect of testosterone on lowering HDL cholesterol is similar. Statin drugs, in doses used clinically, raise HDL cholesterol by 2-3 mg/dL,\textsuperscript{19} similar in magnitude to the reduction of 2.0 mg/dL associated with testosterone treatment in this trial. Ingestion of 17-alkylated androgens, which are abused by athletes, decreases HDL cholesterol much more than testosterone itself.\textsuperscript{20}

The results presented here are important because of the many strengths of the TTrials, including the large number of participants, the placebo-controlled design, raising the median serum testosterone level from unequivocally low to mid-normal for young men, and the excellent participant retention. One limitation of this trial is that the results apply only to older men with low testosterone. Another limitation is that all of the cardiovascular markers assessed were surrogates and not clinical outcomes. Yet another limitation is that we did not assess the function of the lipoproteins, such as the effect of HDL on cholesterol transport.\textsuperscript{21}

The clinical significance of the decreases in cholesterol is uncertain, because both LDL and HDL cholesterol fell, both to small degrees, and insulin and HOMA-IR fell but only slightly. In the 138 men in the TTrials who underwent CT angiography at baseline and month 12, testosterone treatment was associated with a greater increase in noncalcified coronary artery plaque volume than placebo treatment, yet in all TTrials participants, a similar number of men (seven) in each treatment arm experienced major adverse cardiovascular events.\textsuperscript{10} A trial of a much larger number of men treated for a much longer time would be necessary to determine if testosterone treatment of hypogonadal men affects clinical cardiovascular risk.

We conclude that raising the serum testosterone levels of men ≥65 years with low testosterone to normal levels for young men decreases slightly their serum cholesterol and insulin levels, but the clinical significance of these small decreases is unknown.
Grants: The Testosterone Trials were supported by a grant from the National Institute on Aging, National Institutes of Health (U01 AG030644), supplemented by funds from the National Heart, Lung and Blood Institute, National Institute of Neurological Diseases and Stroke, and National Institute of Child Health and Human Development. AbbVie (formerly Solvay and Abbott Laboratories) generously provided funding, AndroGel, and placebo gel. CEL: UAB Diabetes Research and Training Center (DRCT), Grant Number DK-079626 from the National Institute for Diabetes, Digestive and Kidney Diseases, National Institutes of Health; EBC: funding for Rancho Bernardo Study has been supported by National Institutes of Health/National Institute on Aging grants AG07181 and AG028507 and the National Institute of Diabetes and Digestive and Kidney Diseases, grant DK31801; RSS: T32-DK007571; JAC: U01-AG030644 (main) and 5 R01 AG37679 (bone); TMG: is the recipient of an Academic Leadership Award (K07AG043587) from the National Institute on Aging. The Yale Field Center is partially supported by the Claude D. Pepper Older Americans Independence Center (P30AG021342); AMM: was supported by the Department of Veterans Affairs Puget Sound Health Care System U01-AG030644.

Disclosures: Dr. Mohler reports grants from Clarus Pharmaceuticals and Abbvie, outside the submitted work; Dr. Ellenberg reports grants from National Institutes of Health, grants from AbbVie, Inc., during the conduct of the study; grants from AbbVie, Inc., outside the submitted work; Dr. Lewis reports grants from NIH, grants from AbbVie, during the conduct of the study; Dr. Wenger reports grants from Alnylam Pharmaceuticals, grants and personal fees from Gilead Sciences, grants from NHLBI, grants from Pfizer, grants from Society for Women's Health Research, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Merck, outside the submitted work; Dr. Budoff reports grants from NIH, during the conduct of the study; grants from General Electric, outside the submitted work; Dr. Barrett-Connor has nothing to disclose; Dr. Swerdloff reports grants from The Bone Trial of the Testosterone Trial during the conduct of the study; grants and other from Clarus, grants from Lipese, grants and other from Antares, outside the submitted work; Dr. Stephens-Shields reports grants from National Institute on Aging and from AbbVie during the conduct of the study; Dr. Bhasin reports grants from NIA, during the conduct of the study; grants and personal fees from Abbvie, grants and personal fees from Lilly, grants from Transition Therapeutics, grants and personal fees from
Regeneron, outside the submitted work; In addition, Dr. Bhasin has a patent Free testosterone calculator pending and has equity interest in FPT, LLC.; Dr. Cauley has nothing to disclose; Dr. Crandall has nothing to disclose; Dr. Cunningham reports personal fees from AbbVie, Clarus Therapeutics, Endo Pharma, Ferring, Lilly, Merck, Pfizer, and Repros Therapeutics, outside the submitted work; Dr. Ensrud reports grants from National Institute on Aging, during the conduct of the study; Dr. Gill reports grants from the National Institute on Aging during the course of the study; Dr. Matsumoto reports personal fees from AbbVie, Endo, Lilly, Lipocine, Clarus and AYTU, outside the submitted work; Dr. Molitch reports grants from National Institutes of Health, grants from Abbott Laboratories, during the conduct of the study; personal fees from Abbvie (Abbott Laboratories), personal fees from Eli Lilly & Co., personal fees from Pfizer, outside the submitted work; X. Hou has nothing to disclose; D. Cifelli has nothing to disclose; Dr. Snyder reports grants from National Institute on Aging, NIH, grants and non-financial support from AbbVie (formerly Solvay and Abbott Laboratories), during the conduct of the study.

ClinicalTrials.gov number NCT00799617

The TTrials are registered at clinicaltrials.gov http://clinicaltrials.gov/ (NCT00799617).

REFERENCES

Table 1. Characteristics of Participants at Baseline

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Testosterone</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>394</td>
<td>394</td>
<td>394</td>
<td>394</td>
</tr>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>72 ± 5.7</td>
<td>72 ± 5.8</td>
<td>72 ± 5.7</td>
<td>72 ± 5.8</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>175 ± 7.1</td>
<td>175 ± 7.0</td>
<td>175 ± 7.1</td>
<td>175 ± 7.0</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>95 ± 13.1</td>
<td>95 ± 14.0</td>
<td>95 ± 13.1</td>
<td>95 ± 14.0</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>31 ± 3.6</td>
<td>31 ± 3.5</td>
<td>31 ± 3.6</td>
<td>31 ± 3.5</td>
</tr>
<tr>
<td>BMI &gt;30 (%)</td>
<td>251 (63.7%)</td>
<td>246 (62.4%)</td>
<td>251 (63.7%)</td>
<td>246 (62.4%)</td>
</tr>
<tr>
<td>Waist/Hip Ratio</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.1</td>
</tr>
<tr>
<td><strong>Concomitant Conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>148 (37.6%)</td>
<td>144 (36.5%)</td>
<td>148 (37.6%)</td>
<td>144 (36.5%)</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>286 (72.6%)</td>
<td>279 (70.8%)</td>
<td>286 (72.6%)</td>
<td>279 (70.8%)</td>
</tr>
<tr>
<td>History of Myocardial Infarction</td>
<td>53 (13.5%)</td>
<td>63 (16.0%)</td>
<td>53 (13.5%)</td>
<td>63 (16.0%)</td>
</tr>
<tr>
<td>History of Stroke</td>
<td>16 (4.1%)</td>
<td>17 (4.3%)</td>
<td>16 (4.1%)</td>
<td>17 (4.3%)</td>
</tr>
<tr>
<td><strong>Medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antidiabetics</td>
<td>130 (33.0%)</td>
<td>131 (33.2%)</td>
<td>130 (33.0%)</td>
<td>131 (33.2%)</td>
</tr>
<tr>
<td>Lipid-lowering drugs</td>
<td>274 (69.5%)</td>
<td>273 (69.3%)</td>
<td>274 (69.5%)</td>
<td>273 (69.3%)</td>
</tr>
</tbody>
</table>

*Values are mean ± SD or number (%)*
Table 2. Clinical Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Difference in change over time (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline (n)</td>
<td>Month 3 (n)</td>
<td>Month 6 (n)</td>
<td>Month 9 (n)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>94.8 ± 13.1 (394)</td>
<td>94.6 ± 12.9 (374)</td>
<td>94.6 ± 13.1 (367)</td>
<td>94.6 ± 12.9 (356)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.0 ± 3.6 (394)</td>
<td>31.2 ± 3.6 (374)</td>
<td>30.9 ± 3.6 (367)</td>
<td>30.9 ± 3.6 (356)</td>
</tr>
<tr>
<td>Waist/hip ratio (%)</td>
<td>1.0 ± 0.1 (394)</td>
<td>1.0 ± 0.1 (373)</td>
<td>1.0 ± 0.1 (367)</td>
<td>1.0 ± 0.1 (356)</td>
</tr>
</tbody>
</table>

1. Values are means ± SD (number)
2. Average over all observations, adjusting for balancing factors and baseline value. Positive values mean men in the testosterone arm increased more, or decreased less, than men in placebo arm; negative values mean men in placebo arm increased more, or decreased less, than men in testosterone arm.

Table 3. Serum Concentrations of Lipids

<table>
<thead>
<tr>
<th>Assay</th>
<th>Baseline (n)</th>
<th>Month 3 (n)</th>
<th>Month 6 (n)</th>
<th>Month 9 (n)</th>
<th>Month 12 (n)</th>
<th>Baseline (n)</th>
<th>Month 3 (n)</th>
<th>Month 6 (n)</th>
<th>Month 9 (n)</th>
<th>Month 12 (n)</th>
<th>Difference in change over time (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>161.9 ± 37.1 (369)</td>
<td>153.7 ± 35.1 (367)</td>
<td>154.9 ± 32.3 (366)</td>
<td>167.8 ± 33.8 (369)</td>
<td>164.5 ± 36.5 (367)</td>
<td>166.4 ± 34.6 (333)</td>
<td>-6.1 (-8.9, -3.3)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL Cholesterol (mg/dL)</td>
<td>44.5 ± 12.7 (369)</td>
<td>41.8 ± 12.2 (367)</td>
<td>43.1 ± 12.6 (365)</td>
<td>45.5 ± 14.4 (368)</td>
<td>44.8 ± 13.3 (367)</td>
<td>45.3 ± 13.1 (333)</td>
<td>-2.0 (-2.9, -1.0)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-HDL Cholesterol (mg/dL)</td>
<td>117.4 ± 37.2 (369)</td>
<td>111.9 ± 34.7 (367)</td>
<td>111.8 ± 31.9 (364)</td>
<td>122.2 ± 35.2 (369)</td>
<td>119.7 ± 37.1 (367)</td>
<td>119.3 ± 35.4 (333)</td>
<td>-4.2 (-7.1, -1.3)</td>
<td>0.005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL Cholesterol (mg/dL)</td>
<td>87.9 ± 28.9 (363)</td>
<td>84.0 ± 28.2 (360)</td>
<td>84.9 ± 27.7 (341)</td>
<td>91.8 ± 29.6 (360)</td>
<td>89.1 ± 30.5 (363)</td>
<td>89.7 ± 27.8 (325)</td>
<td>-2.3 (-4.6, 0.01)</td>
<td>0.051</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol/HDL Ratio</td>
<td>3.9 ± 2.1 (369)</td>
<td>4.0 ± 1.5 (367)</td>
<td>3.9 ± 1.6 (346)</td>
<td>4.0 ± 1.4 (369)</td>
<td>4.0 ± 1.4 (367)</td>
<td>3.9 ± 1.4 (333)</td>
<td>0.02 (-0.1, 0.2)</td>
<td>0.81</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>150.1 ± 149.3 (369)</td>
<td>145.6 ± 136.0 (367)</td>
<td>140.7 ± 142.6 (346)</td>
<td>153.4 ± 84.3 (367)</td>
<td>151.3 ± 81.2 (367)</td>
<td>145.1 ± 77.5 (333)</td>
<td>-4.0 (-14.7, 6.8)</td>
<td>0.47</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Values are means ± SD and (number of participants)
2. Average over all observations, adjusting for balancing factors and baseline value. Positive values mean men in the testosterone arm increased more, or decreased less, than men in placebo arm; negative values mean men in placebo arm increased more, or decreased less, than men in testosterone arm.

Table 4. Markers of Glucose Metabolism

<table>
<thead>
<tr>
<th>Assay</th>
<th>Baseline (n)</th>
<th>Month 3 (n)</th>
<th>Month 12 (n)</th>
<th>Baseline (n)</th>
<th>Month 3 (n)</th>
<th>Month 12 (n)</th>
<th>Difference in change over time (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dL)</td>
<td>114.4 ± 28.2 (369)</td>
<td>113.6 ± 32.4 (367)</td>
<td>115.7 ± 30.9 (346)</td>
<td>116.0 ± 27.8 (369)</td>
<td>116.1 ± 29.1 (367)</td>
<td>118.2 ± 35.2 (333)</td>
<td>-1.5 (-4.3, 1.3)</td>
<td>0.30</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>19.6 ± 19.0 (367)</td>
<td>17.3 ± 12.5 (365)</td>
<td>17.9 ± 13.6 (342)</td>
<td>17.5 ± 12.2 (364)</td>
<td>19.2 ± 14.8 (365)</td>
<td>19.3 ± 14.9 (330)</td>
<td>-1.7 (-3.1, 0.3)</td>
<td>0.02</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>5.8 ± 6.3 (367)</td>
<td>5.1 ± 4.6 (365)</td>
<td>5.5 ± 6.4 (342)</td>
<td>5.8 ± 6.0 (364)</td>
<td>5.9 ± 6.2 (365)</td>
<td>5.6 ± 5.5 (330)</td>
<td>-0.6 (-1.2, 0.1)</td>
<td>0.03</td>
</tr>
<tr>
<td>Hgb A1C (%)</td>
<td>6.3 ± 0.8 (249)</td>
<td>---</td>
<td>6.3 ± 0.9 (250)</td>
<td>6.3 ± 0.8 (243)</td>
<td>---</td>
<td>6.4 ± 1.0 (242)</td>
<td>-0.07 (-0.2, 0.01)</td>
<td>0.09</td>
</tr>
</tbody>
</table>

1. Values are means ± SD and (number of participants)
2. Average over all observations, adjusting for balancing factors and baseline value. Positive values mean men in the testosterone arm increased more, or decreased less, than men in placebo arm; negative values mean men in placebo arm increased more, or decreased less, than men in testosterone arm.
3. HOMA-IR. Homeostatic model assessment of insulin resistance, calculated as glucose x insulin /22.5.
Hgb A1c. Hemoglobin A1c. Collection of blood for hgb A1c was not begun until after the trial was underway, so the n is smaller for this parameter.

Table 5. Other Markers

<table>
<thead>
<tr>
<th>Assay</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Difference in change over time</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline (n)</td>
<td>Month 3 (n)</td>
<td>Baseline (n)</td>
<td>Month 3 (n)</td>
</tr>
<tr>
<td>D-dimer (mg/L)</td>
<td>0.7 ± 0.6 (370)</td>
<td>0.8 ± 1.2 (367)</td>
<td>0.8 ± 0.6 (351)</td>
<td>0.7 ± 0.6 (367)</td>
</tr>
<tr>
<td>CRP* (mg/L)</td>
<td>3.5 ± 9.4 (363)</td>
<td>3.4 ± 6.2 (363)</td>
<td>2.8 ± 3.8 (347)</td>
<td>3.5 ± 5.6 (363)</td>
</tr>
<tr>
<td>IL-6* (pg/mL)</td>
<td>1.9 ± 5.8 (372)</td>
<td>2.0 ± 1.9 (371)</td>
<td>2.8 ± 18.3 (352)</td>
<td>2.0 ± 2.4 (371)</td>
</tr>
<tr>
<td>Troponin (ng/mL)</td>
<td>7.6 ± 7.4 (317)</td>
<td>9.1 ± 9.7 (316)</td>
<td>10.0 ± 15.0 (262)</td>
<td>9.1 ± 18.3 (307)</td>
</tr>
</tbody>
</table>

1. Values are means ± SD and (number of participants)
2. Average over all observations, adjusting for balancing factors and baseline value. Positive values mean men on testosterone arm increased more, or decreased less, than men on placebo arm; negative values mean men in placebo arm increased more, or decreased less, than men on testosterone arm.
3. CRP. C-reactive protein
4. IL-6. Interleukin 6.